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A B S T R A C T
Introduction. Premature ejaculation (PE) is deﬁned by short ejaculatory latency and inability to delay ejaculation
causing distress. Management may involve behavioral and/or pharmacological approaches.
Aim. To systematically review the randomized controlled trial (RCT) evidence for behavioral therapies in the
management of PE.
Methods. Nine databases including MEDLINE were searched up to August 2014. Included RCTs compared
behavioral therapy against waitlist control or another therapy, or behavioral plus drug therapy against drug treatment
alone. [Correction added on 10 September 2015, after ﬁrst online publication: Search period has been amended from
August 2013 to August 2014.]
Main Outcome Measure. Intravaginal ejaculatory latency time (IELT), sexual satisfaction, ejaculatory control, and
anxiety and adverse effects.
Results. Ten RCTs (521 participants) were included. Overall risk of bias was unclear. All studies assessed physical
techniques, including squeeze and stop-start, sensate focus, stimulation device, and pelvic ﬂoor rehabilitation. Only
one RCT included a psychotherapeutic approach (combined with stop-start and drug treatment). Four trials
compared behavioral therapies against waitlist control, of which two (involving squeeze, stop-start, and sensate focus)
reported IELT differences of 7–9 minutes, whereas two (web-based sensate focus, stimulation device) reported no
difference in ejaculatory latency posttreatment. For other outcomes (sexual satisfaction, desire, and self-conﬁdence),
some waitlist comparisons signiﬁcantly favored behavioral therapy, whereas others were not signiﬁcant. Three trials
favored combined behavioral and drug treatment over drug treatment alone, with small but signiﬁcant differences in
IELT (0.5–1 minute) and signiﬁcantly better results on other outcomes (sexual satisfaction, ejaculatory control, and
anxiety). Direct comparisons of behavioral therapy vs. drug treatment gave mixed results, mostly either favoring drug
treatment or showing no signiﬁcant difference. No adverse effects were reported, though safety data were limited.
Conclusions. There is limited evidence that physical behavioral techniques for PE improve IELT and other out-
comes over waitlist and that behavioral therapies combined with drug treatments give better outcomes than drug
treatments alone. Further RCTs are required to assess psychotherapeutic approaches to PE. Cooper K, Martyn-St
James M, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, and Hood C. Behavioral therapies
for management of premature ejaculation: A systematic review. Sex Med 2015;3:174–188.
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Introduction
Premature ejaculation (PE) is a male sexualdysfunction characterized by short ejacula-
tory latency. PE can be either lifelong (primary,
present since ﬁrst sexual experiences) or acquired
(secondary, beginning later). The 2014 update of
the International Society for Sexual Medicine
(ISSM) Guidelines for the Diagnosis and Treat-
ment of Premature Ejaculation deﬁne PE as a
combination of (i) ejaculation usually occurring
within about 1 minute of vaginal penetration (for
lifelong PE) or a clinically signiﬁcant reduction in
latency time, often to around 3 minutes or less (for
acquired PE); (ii) inability to delay ejaculation;
and (iii) negative personal consequences such as
distress, bother, frustration, and/or the avoidance
of sexual intimacy [1]. PE is similarly deﬁned by
Diagnostic and Statistical Manual of Mental Dis-
orders 5 (DSM 5) (2013) as ejaculation usually
occurring within about 1 minute of vaginal pen-
etration and before the individual wishes it and
causing clinically signiﬁcant distress [1]. Estimat-
ing the prevalence of PE is not straightforward
due to the difﬁculty in deﬁning what constitutes
clinically relevant PE. Surveys have estimated the
prevalence of Diagnostic and Statistical Manual of
Mental Disorders IV-deﬁned PE as 20–30%
[2–4]; however, these estimates are likely to
include men who have some concern about their
ejaculatory function but do not meet the current
diagnostic criteria for PE [1]. It has been sug-
gested that the prevalence of lifelong PE accord-
ing to the ISSM and DSM-5 deﬁnitions (with an
ejaculatory latency of about 1 minute) is unlikely
to exceed 4% [1]. Men with PE are more likely to
report lower levels of sexual functioning and sat-
isfaction, and higher levels of personal distress and
interpersonal difﬁculty, than men without PE [5].
They may also rate their overall quality of life as
lower than that of men without PE [5]. In addi-
tion, their partner’s satisfaction with the sexual
relationship has been reported to decrease with
increasing severity of the condition [6]. Manage-
ment of PE may involve a range of interventions.
These include systemic drug treatments (such as
selective serotonin reuptake inhibitors, tricyclic
antidepressants, phosphodiesterase type 5 inhibi-
tors, and analgesics), topical anesthetic creams and
sprays, and behavioral therapies (BTs) [7,8].
Behavioral and psychological therapies for PE
include two main classes of therapy, with over-
lapping elements [1]. The ﬁrst consists of psy-
chotherapy (such as psychosexual or relationship
counselling) for men and/or couples, to address
psychological and interpersonal issues that may
be contributing to PE. The second consists of
physical techniques to help men develop sexual
skills to delay ejaculation and improve sexual self-
conﬁdence. Speciﬁc physical techniques include
the following. The “stop-start” technique, devel-
oped by Semans, involves the man or his partner
stimulating the penis until he feels the urge to
ejaculate, then stopping until the sensation
passes; this is repeated a few times before allow-
ing ejaculation to occur [9]. The aim is to learn
to recognize the feelings of arousal in order to
improve control over ejaculation. With the
related “squeeze” technique, proposed by Masters
and Johnson, the man’s partner stimulates the
penis until he feels the urge to ejaculate, then
squeezes the glans of the penis until the sensation
passes; this is repeated before allowing ejacula-
tion to occur [9]. Within sensate focus or sensate
focusing [7], the man and his partner begin by
focusing on touch, which excludes breasts, geni-
tals, and intercourse, to encourage body aware-
ness while reducing performance anxiety; this is
followed by gradual reintroduction of genital
touching and then full intercourse [10]. Pelvic
ﬂoor muscle rehabilitation exercises may also
assist with ejaculatory control [11].
The aim of this study was to systematically
review the evidence base for BTs in the manage-
ment of PE.
Methods
Review Methods
The review was undertaken in accordance with
the general principles recommended in the Pre-
ferred Reporting Items for Systematic Reviews
and Meta-Analyses statement (http://www.prisma-
statement.org/). The review protocol is available
from the Health Technology Assessment Pro-
gramme website (http://www.nets.nihr.ac.uk/
projects/hta/131201).
Literature Searches
The following databases were searched up to
August 2014: MEDLINE; Embase; Cumulative
Index to Nursing and Allied Health Literature;
The Cochrane Library including the Cochrane
Systematic Reviews Database, Cochrane Con-
trolled Trials Register, Database of Abstracts of
Reviews of Effects and the Health Technology
Assessment database; ISI Web of Science,
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including Science Citation Index, and the Confer-
ence Proceedings Citation Index-Science. The
Medline search strategy is provided in Supplemen-
tary Appendix S1; it should be noted that the
search was undertaken as part of a wider project
assessing a variety of treatments for PE [12], and
for this reason, the search was not speciﬁc to BTs.
The U.S. Food and Drug Administration website
and the European Medicines Agency website were
also searched. Existing systematic reviews and rel-
evant studies were also checked for eligible studies.
Eligibility Criteria
Randomized controlled trials (RCTs) in adult men
with PE that evaluated BTs were eligible for inclu-
sion. Studies comparing a BT against a waitlist
control or against another therapy were eligible, as
were studies comparing a combination of BT plus
drug treatment against drug treatment alone.
Studies were not included if the same BT was
provided in both arms, as these were not consid-
ered to be assessing the effect of the BT (e.g.,
studies of drug plus behavioral treatment vs.
behavioral alone). Theses and dissertations were
not included. Non-English publications were
included where sufﬁcient data could be extracted
from an English-language abstract or tables.
Outcomes
Relevant outcomes included intravaginal ejacula-
tory latency time (IELT), other measures of ejacu-
latory latency, and other outcomes such as sexual
satisfaction, control over ejaculation, relationship
satisfaction, self-esteem, quality of life, treatment
acceptability, and adverse events.
Data Extraction and Synthesis
One reviewer performed data extraction of each
study; all numerical data were then checked by a
second reviewer. Where possible, data were pre-
sented as forest plots using Cochrane RevMan
software (version 5.2; The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenha-
gen, Denmark) (RevMan 2014) [13].
Assessment of Methodological Quality of Studies
Methodological quality of included RCTs was
assessed using the Cochrane Collaboration risk of
bias assessment criteria [14]. Completeness of
outcome data was considered low risk if the per-
centage of randomized participants excluded from
the primary analysis was less than 30%. Selective
reporting was considered low risk if IELT or
ejaculatory latency was reported, and all outcomes
referred to in the study methods were reported.
Overall risk of bias for each study was classed as
“low” or “high” if they were rated as such for each
of three key domains: allocation concealment,
blinding of outcome assessment, and completeness
of outcome data; otherwise, overall risk of bias was
classed as “unclear.”
Results
Quantity of Evidence
The searches identiﬁed 2,283 citations (as part of a
wider project assessing a variety of treatments for
PE). Eighteen full-text articles were obtained as
potentially relevant. A total of 10 RCTs (521 ran-
domized participants) evaluating a BT for PE were
included in the review.
Characteristics of Included Studies
Details of the included study characteristics are
presented in Table 1. As noted earlier, BTs for PE
include two main types of therapy: ﬁrst, psycho-
therapeutic or counseling approaches, and second
physical techniques. Interestingly, this review
identiﬁed only one RCT involving psychotherapy
for PE: a Chinese study [19] in which one
group received a combination of drug treatment
(chlorpromazine) plus psychotherapy (to reduce
anxiety, sadness, and negative thoughts and rebuild
conﬁdence) plus the stop-start technique, whereas
the other group received chlorpromazine alone.
All other included RCTs focused on physical tech-
niques, either individually or in combination. The
speciﬁc BTs that were evaluated included: the
squeeze technique [22]; the stop-start technique
[21,23]; the stop-start and squeeze techniques [15];
the stop-start technique plus psychotherapy [19];
functional-sexological treatment involving educa-
tion on sensuality, movement of the body, speed of
sexual activity, muscular tension and breathing
[15]; self-help material (covering squeeze tech-
nique, pause technique, and sensate focusing) with
or without therapist phone contact [17]; sexual
therapy for couples (sensate focus, stop-start tech-
nique, and communication exercises) [17]; pelvic
ﬂoor muscle rehabilitation (awareness of muscle
contraction) plus electrical stimulation of perineal
ﬂoor [11]; squeeze technique, sensate focus, and
Chinese traditional Qigong treatment (penis
swinging and acupoint tapping) [20]; web-based
sex therapy based on sensate-focus [18]; and the
stop-start technique using a handheld vibrating
stimulation device [16].
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Duration of the behavioral intervention in
the included studies ranged from 2 to 12 weeks.
Four studies compared one or more behavioral
techniques with a waitlist control [15–18]. Three
further studies compared a BT with one or more
drug treatments [11,22,23], whereas another three
studies compared combined therapy (behavioral
and drug) vs. drug treatment alone [19–21].
Studies were conducted in a range of countries:
three in China (published in Chinese language)
[19–21], two in Canada [15,17], and one each in
Egypt [22], Turkey [23], Italy [11], the Nether-
lands [18], and Finland [16]. The deﬁnition of PE
was an IELT of <1 minute in one study [19], ≤2
minutes in two studies [15,22], ≤5 minutes in one
study [17], deﬁned according to the ISSM deﬁni-
tion in one study [11], “before or within several
minutes” in one study [23], and was not reported
(or not available in the English language text) in
four studies [16,18,20,21]. Three studies reported
that participants had lifelong PE [11,16,22],
whereas in one study participants had lifelong or
acquired PE [23]; for the remaining studies, this
was not reported (or not available in the English
language text).
Of the 10 studies, one did not report IELT [23],
whereas the remaining nine reported either IELT
(in minutes) or another measure of ejaculatory
latency (Table 2). Of these, four studies reported
stopwatch-assessed IELT [11,15,16,22]; three
studies reported IELT in minutes, but the mea-
surement method was not reported (or not avail-
able in English-language text) [17,19,21]; one
study reported tendency to ejaculate too soon as
measured via the Golombok Rust Inventory of
Sexual Satisfaction (GRISS) PE subscale [18]; and
one study reported ejaculatory latency as measured
on the Chinese Index of Premature Ejaculation-5
(CIPE-5) ﬁve-point Likert scale [20].
Risk of Bias in Included Studies
The risk of bias within included studies is shown in
Table 1. All 10 studies were classed as overall
unclear risk of bias due to limited reporting of
methodological details (three studies [19–21] were
reported in Chinese, and some details were
unavailable from the English language text). In
total, eight studies [15–17,19–23] were unclear in
terms of randomization sequence generation and
nine [11,15–21,23] were unclear in terms of allo-
cation concealment. Due to the nature of the
interventions, blinding of participants and person-
nel was not possible in any study. Blinding of
outcome assessment was unclear in all studies.
Eight studies [11,16,18–23] were considered at low
risk of bias for completeness of outcome data
(<30% excluded from primary analysis), whereas
two [15,17] were unclear on this point. All studies
scored low for selective reporting (based on the
fact that they reported IELT or ejaculatory latency
as well as all outcomes referred to in the methods
sections), with the exception of one study [23] that
did not report IELT or ejaculatory latency.
Assessment of Effectiveness: IELT and
Ejaculatory Latency
BT vs.Waitlist
Four studies assessed BTs vs. waitlist control
[15–18]. Two signiﬁcantly favored BTs in terms of
IELT, whereas one showed no difference on
another measure of ejaculatory latency (Table 2;
Figures 1–3).
Functional-Sexological Treatment or Squeeze/
Stop-Start vs.Waitlist
A study by de Carufel and Trudel (2006; n = 36
couples) [15] assessed two types of BT vs. waitlist
control: functional-sexological therapy (FS,
involving education on sensuality, movement of
the body, speed of sexual activity, muscular tension
and breathing) and BT (involving the squeeze and
stop-start techniques). Duration of treatment
was not reported. Both treatments improved
stopwatch-measured IELT signiﬁcantly more than
waitlist at posttreatment, by almost 7 minutes
(Table 2; Figure 1). Follow-up data 3 months post-
treatment was available for the FS and BT groups
(though not for waitlist); in both groups, the sig-
niﬁcant change in IELT from baseline to post-
treatment remained signiﬁcant 3 months after
treatment cessation.
Stop-Start Using Handheld Device vs.Waitlist
A small study by Jern (n = 11 participants) [16]
assessed the stop-start technique aided by a hand-
held vibrating stimulation device vs. waitlist
control. Participants used the device, alone or with
a partner, three times per week for 6 weeks. After
6 weeks, ejaculatory latency improved slightly
more in the treatment group (improvement of 1.6
minutes; P = 0.019 for change from baseline) than
in the waitlist group (0.9 minutes; P = 0.075 for
change); however, the posttreatment scores were
not signiﬁcantly different (mean difference [MD]
0.35 minutes, 95% conﬁdence interval [CI] −2.26
to 2.96; P = 0.79; Table 2 and Figure 1). At
follow-up 6 months after all patients undertook
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treatment, IELT had improved by 1.7 minutes
from baseline (P = 0.008 for change).
Self-Help Book with/Without Therapist Contact
or Couples’ Sexual Therapy vs.Waitlist
A further RCT by Trudel and Proulx (n = 25
couples) [17] assessed three types of BT vs. waitlist
control: self-help book alone (described as
bibliotherapy); self-help book plus therapist phone
contact; and sexual therapy for couples. After 12
weeks, all gave improvements in IELT of between
7 and 9 minutes over that of the waitlist group,
though the method of IELT measurement was not
stated, with changes from baseline signiﬁcant for
all treatment groups (P < 0.01) but not for the
waitlist group (P value not reported; Table 2).
Figure 1 Behavioral therapies vs. waitlist: IELT and ejaculatory latency
Figure 2 Behavioral plus drug therapy vs. drug alone: IELT and ejaculatory latency
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These data could not be presented on the forest
plot as no standard deviations were reported.
Changes from baseline in the treatment groups
remained signiﬁcant 3 and 6 months after treat-
ment cessation.
Web-Based Sex Therapy vs.Waitlist
A third RCT by van Lankveld et al. [18] (n = 40
participants) assessed web-based sex therapy (using
sensate focus) vs. waitlist. The GRISS-PE subscale
was used to measure the extent to which a man has
the tendency to ejaculate too soon. There was
almost no difference between groups at 12 weeks
(score of 13 in both groups; P = 0.80; Table 2 and
Figure 1). Both groups improved from baseline
(P < 0.001), and the change in the sex therapy
group remained signiﬁcant at 3 and 6 months after
treatment cessation (no follow-up data were avail-
able for waitlist).
Combined Behavioral and Drug Therapy vs.
Drug Alone
Three studies compared behavioral and drug com-
bination therapy vs. drug treatment alone; all
showed small but signiﬁcant differences in IELT
or ejaculatory latency favoring the combined
approach [19–21].
BT Plus Chlorpromazine vs. Chlorpromazine
One RCT by Li et al. (n = 90 participants)
[19] assessed combined therapy (BT plus
chlorpromazine, a dopamine antagonist; 50 mg/
day) vs. chlorpromazine alone. BT consisted of the
stop-start technique plus psychotherapy (to reduce
anxiety, sadness, and negative thoughts and rebuild
conﬁdence). Combined therapy gave a greater
increase in IELT at 6 weeks, though the difference
was only 1 minute, and the measurement method
was not reported (MD 1.11 minutes, 95% CI 0.86
to 1.36; P < 0.00001; Table 2 and Figure 2).
BT Plus Paroxetine vs. Paroxetine
Another RCT by Shao et al. (n = 80 participants
for this comparison) [20] assessed BT plus
paroxetine (a selective serotonin reuptake inhibi-
tor [SSRI]) vs. paroxetine alone. BT included
squeeze technique, sensate focus, Qigong and
acupoint tapping and was provided for 8 weeks.
The paroxetine dose was 10 mg/day for 4 weeks in
the combined therapy group and 20 mg/day for 8
weeks in the paroxetine-only group. Combined
therapy was superior to paroxetine alone in
increasing ejaculatory latency at 8 weeks as mea-
sured on a ﬁve-point Likert scale via the CIPE-5,
though the difference was small (MD 0.40,
95% CI 0.18 to 0.62; P = 0.0003; Table 2 and
Figure 2).
BT Plus Citalopram vs. Citalopram
A further RCT by Yuan et al. (n = 64 participants
for this comparison) [21] reported that BT (stop-
start technique) plus citalopram (an SSRI; 20 mg/
day) was superior to citalopram alone in
increasing IELT at 6 weeks, though the IELT
difference was only 0.5 minutes, and the mea-
surement method was not reported (MD 0.46
minutes, 95% CI 0.04 to 0.88; P = 0.03; Table 2
and Figure 2).
Figure 3 Behavioral therapy vs. drug treatment: IELT and ejaculatory latency
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BT vs. Drug Treatment
Four studies compared BT alone vs. drug treat-
ment alone; all showed small but signiﬁcant differ-
ences in IELT or ejaculatory latency favoring drug
treatment [11,20–22].
Pelvic Floor Rehabilitation vs. Dapoxetine
One RCT by Pastore et al. (n = 40 participants)
[11] compared pelvic ﬂoor rehabilitation (plus
electrical stimulation of the perineum) vs.
dapoxetine (an SSRI, 30 or 60 mg taken prior to
intercourse). The between-group difference in
geometric mean stopwatch-assessed IELT at 12
weeks was 1.22 minutes in favor of dapoxetine
(MD 1.22, 95% CI 0.79 to 1.65; P < 0.0001;
Table 2 and Figure 3).
BT vs. Paroxetine
The RCT by Shao et al. (n = 80 participants for
this comparison) [20] compared paroxetine
(20 mg/day) against BT (squeeze technique,
sensate focus, Qigong and acupoint tapping). The
between-group difference in the CIPE-5 ejacula-
tory latency score at 8 weeks signiﬁcantly favored
paroxetine (MD 0.20, 95% CI 0.00 to 0.40;
P = 0.05; Table 2 and Figure 3).
BT vs. Citalopram
The RCT by Yuan et al. (n = 64 participants for
this comparison) [21] reported a between-group
difference in IELT at 6 weeks of 3.55 minutes in
favor of citalopram (20 mg/day) compared with
BT (stop-start technique); MD 3.55, 95% CI 3.22
to 3.88; P < 0.00001; Table 2 and Figure 3). The
measurement method was not reported.
Squeeze Technique vs. SSRIs or Tricyclic
Antidepressants (TCA)
The between-group difference in median
stopwatch-measured IELT following a 4-week ran-
domized crossover comparison (Abdel-Hamid
et al.; n = 31 participants) [22] signiﬁcantly favored
sildenaﬁl or paroxetine over BT (pause-squeeze
technique), whereas comparisons with sertraline
and clomipramine were not signiﬁcant (Table 2).
Data were not presented on the forest plot due to
the reporting of median rather than mean values.
Assessment of Effectiveness: Non-IELT Outcomes
With the exception of the RCT by Pastore et al.
[24], all of the included trials were reported as
evaluating one or more outcomes other than IELT
(Table 3). However, these were diverse across the
included trials and were not reported in sufﬁcient
detail to permit any pooling across trials.
BT vs.Waitlist Control
Four RCTs assessed non-IELT outcomes for BTs
vs. waitlist control; one signiﬁcantly favored BTs
[15], whereas the other two were unclear as to
whether there was a signiﬁcant difference between
groups [16–18]. One RCT (de Carufel and Trudel)
[15] showed signiﬁcant improvements in male per-
ception of duration of intercourse and couples’
sexual satisfaction with either functional sexologi-
cal treatment (sensual education) or BT (stop-start
technique and squeeze technique) compared with
waitlist control. Another RCT (Trudel and Proulx)
[17] reported a signiﬁcant increase from baseline
in sexual satisfaction for all three BT groups (self-
help book, self-help book plus therapist phone
contact, and sexual therapy) with better results for
self-help plus phone contact vs. self-help alone;
however, no data were reported for the waitlist
group. A further RCT (van Lankveld et al.) [18]
reported that sexual desire improved signiﬁcantly
more with web-based sensate focus than waitlist
control, whereas sexual satisfaction improved from
baseline but showed no signiﬁcant difference
between groups; conversely, self-conﬁdence
showed no signiﬁcant difference either between
groups or from baseline. A small RCT using the
stop-start technique aided by a handheld stimula-
tion device (Jern) [16] showed no signiﬁcant
improvement over waitlist or from baseline post-
treatment (via a composite score for ejaculatory
latency, control and relationship problems);
however, a signiﬁcant improvement from baseline
was observed at 6-month follow-up (at which
point all patients had received treatment so there
was no waitlist comparison).
Combined Behavioral + Drug Therapy vs. Drug Alone
Three RCTs reported better results for combined
therapy (behavioral plus drug) than drug treatment
alone on a range of non-IELT outcomes [19–21].
BT (stop-start plus psychotherapy) combined with
chlorpromazine was reported by one RCT as
being more effective than chlorpromazine alone
on a self-rated measure of anxiety and CIPE mea-
sures of sexual anxiety, sexual satisfaction, and
ejaculatory control (Li et al.) [19]. Another RCT
(Shao et al.) [20] reported that combined treat-
ment with paroxetine plus BT (squeeze, sensate
focus, Qigong and acupoint tapping) was superior
to paroxetine alone on CIPE measures of ejacula-
tory control, patient/partner satisfaction, and
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sexual anxiety. A further RCT (Yuan et al.) [21]
reported that BT (stop-start technique) combined
with citalopram was more effective at improving
sexual satisfaction than citalopram alone, though
signiﬁcance level was not reported.
BT vs. Drug Treatment
Four RCTs [20–23] comparing BTs vs. drug treat-
ment reported non-IELT outcomes, with mixed
results (some outcomes favoring drug treatment,
some behavioral, and some showing no differ-
ence). One RCT (Shao et al.) [20] reported mixed
results; results for CIPE-assessed ejaculatory
control signiﬁcantly favored paroxetine over BT,
whereas results for patient/partner satisfaction sig-
niﬁcantly favored BT, and there was no signiﬁcant
difference in sexual anxiety. Yuan et al. [21]
reported that citalopram signiﬁcantly improved
sexual satisfaction compared with BT (stop-start).
Oguzhanglu et al. [23] reported no signiﬁcant
between-group difference in sexual satisfaction for
stop-start technique compared with ﬂuoxetine
(though both groups improved from baseline). A
crossover RCT (Abdel-Hamid et al.) [22] reported
signiﬁcantly better sexual satisfaction with
sildenaﬁl or paroxetine compared with the squeeze
technique but no signiﬁcant differences compared
with clomipramine or sertraline, whereas anxiety
was not signiﬁcantly different between groups.
Assessment of Adverse Effects and Withdrawals
from Treatment
Adverse effect data were available for six of 10
studies [11,16,17,20,22,23]. None reported any
adverse effects for BTs. One study (Trudel and
Proulx) [17] reported that dropout rates from
treatment were higher for the group receiving self-
help material alone (45%) than for the two groups
with therapist contact (14% and 33%; unclear
which data relate to which of the two therapist-
contact groups).
Adverse event rates reported for groups receiv-
ing drug treatment or combined drug and behav-
ioral treatment were as follows: 10% for
paroxetine 10 mg/day (plus BT) [20]; 40% for
paroxetine 20 mg/day [20]; 17% for paroxetine
20 mg taken pre-coitus [22]; 10% for sertraline
50 mg pre-coitus [22], 13% for ﬂuoxetine [23];
13% for dapoxetine 30 mg pre-coitus [11]; 29%
for dapoxetine 60 mg pre-coitus [11]; 25% for clo-
mipramine 25 mg pre-coitus [22]; and 18% for
sildenaﬁl 50 mg pre-coitus [22]. Where reported,
adverse effects of SSRIs included nausea, diarrhea,
dry mouth, anorexia, drowsiness, and yawning
[11,22,23], whereas adverse effects of sildenaﬁl
(phosphodiesterase type 5 inhibitors) included
headache, ﬂushing, and nasal congestion [22].
Summary of Effectiveness Results
The effectiveness results across trials are summa-
rized in Table 4. Four trials compared BTs against
waitlist [15–18]. Of these, two trials assessing ﬁve
types of BT reported posttreatment differences in
IELT of 7–9 minutes compared with the waitlist
groups, with changes in the treatment groups
maintained 3 months after treatment cessation
[15,17]. However, a further trial showed no differ-
ence in ejaculatory latency via the GRISS-PE scale
between web-based sensate focus and waitlist,
though both groups improved from baseline [18].
Another trial showed no posttreatment difference
in IELT between the stop-start technique aided by
a stimulation device vs. waitlist, though there was a
signiﬁcant improvement from baseline at 6-month
follow-up [16]. Results were mixed for other
outcomes (sexual satisfaction, desire, and self-
conﬁdence), with some waitlist comparisons sig-
niﬁcantly favoring BT while others were not
signiﬁcant [15–18].
Three trials favored combined behavioral and
drug treatment over drug treatment alone [19–
21], with small but signiﬁcant differences in IELT
favoring combined treatment (0.5–1 minute across
two trials) [19,21] and signiﬁcantly better results
for combined treatment on other outcomes
(sexual satisfaction, ejaculatory control, and
anxiety) [19–21]. Direct comparisons of BT alone
or drug treatment alone gave mixed results both
for IELT and other outcomes, with most ﬁndings
either favoring drug treatment or showing no sig-
niﬁcant difference.
Discussion
This systematic review assesses the effectiveness of
BTs for the treatment of PE, based on RCT evi-
dence. Ten trials were identiﬁed; these were con-
ducted across various countries and the overall risk
of bias was unclear in all studies. The included
studies assessed various types of BT either indi-
vidually or in combination, including the squeeze
and stop-start techniques, stop-start aided by a
stimulation device, education on sensuality and
movement, sensate focus, and pelvic ﬂoor muscle
rehabilitation. All the above showed some evi-
dence of effectiveness either over waitlist or as an
Review Behaviour Therapy for Premature Ejaculation 185
Sex Med 2015;3:174–188© 2015 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
Ta
bl
e
4
Su
m
m
ar
y
o
fr
e
su
lts
O
ut
co
m
e
R
CT
s
N
pt
ps
In
te
rv
en
tio
n
Co
m
pa
ra
to
r
M
ea
n
di
ff.
(95
%
CI
),
P
va
lu
e
Fa
vo
rs
B
eh
av
io
ra
lt
he
ra
py
v
s.
w
ai
tli
st
IE
LT
(m
inu
tes
)
de
Ca
ru
fe
la
n
d
Tr
u
de
l[1
5]
36
BT
(sq
ue
ez
e,
st
op
-s
ta
rt)
W
a
itl
is
t
6.
87
(5.
10
to
8.
64
),
P
<
0.
00
00
1
BT
BT
(F
S)
W
a
itl
is
t
6.
80
(5.
04
to
8.
56
),
P
<
0.
00
00
1
BT
Tr
u
de
la
n
d
Pr
ou
lx
[17
]
25
BT
(se
lf-h
elp
)
W
a
itl
is
t
9.
11
(N
R)
BT
BT
(se
lf-h
elp
+
ph
on
e)
W
a
itl
is
t
7.
29
(N
R)
BT
BT
(co
up
les
th
er
ap
y)
W
a
itl
is
t
8.
84
(N
R)
BT
Je
rn
[16
]
11
BT
(st
op
-st
art
+
de
vic
e)
W
a
itl
is
t
0.
35
(−2
.2
6
to
2.
96
),
P
=
0.
79
N
ot
si
gn
ific
an
t
Eja
cu
lat
ory
la
te
nc
y
(G
RI
SS
-P
E)
va
n
La
nk
ve
ld
e
ta
l.
[18
]
40
BT
(w
eb
-ba
se
ds
e
n
sa
te
fo
cu
s)
W
a
itl
is
t
−0
.2
0
(−1
.7
5
to
1.
35
),
p=
0.
80
N
ot
si
gn
ific
an
t
Se
xu
al
sa
tis
fa
ct
io
n
de
Ca
ru
fe
la
n
d
Tr
u
de
l[1
5]
36
BT
(tw
ot
yp
es
;s
e
e
a
bo
ve
)
W
a
itl
is
t
P
=
N
R
BT
Tr
u
de
la
n
d
Pr
ou
lx
[17
]
25
BT
(th
ree
ty
pe
s;
se
e
a
bo
ve
)
W
a
itl
is
t
P
=
N
R
Un
cle
ar
va
n
La
nk
ve
ld
e
ta
l.
[18
]
40
BT
(w
eb
-ba
se
ds
e
n
sa
te
fo
cu
s)
W
a
itl
is
t
P
=
N
R
N
ot
si
gn
ific
an
t
Pe
rc
ep
tio
n
o
fd
ur
at
io
n
de
Ca
ru
fe
la
n
d
Tr
u
de
l[1
5]
36
BT
(tw
ot
yp
es
;s
e
e
a
bo
ve
)
W
a
itl
is
t
P
<
0.
05
BT
Se
xu
al
de
sir
e
va
n
La
nk
ve
ld
e
ta
l.
[18
]
40
BT
(w
eb
-ba
se
ds
e
n
sa
te
fo
cu
s)
W
a
itl
is
t
P
<
0.
05
BT
Se
lf-
co
nfi
de
nc
e
va
n
La
nk
ve
ld
e
ta
l.
[18
]
40
BT
(w
eb
-ba
se
ds
e
n
sa
te
fo
cu
s)
W
a
itl
is
t
P
=
N
R
N
ot
si
gn
ific
an
t
Eja
cu
lat
ory
co
n
tro
l,
la
te
nc
y,
pr
ob
le
m
s
Je
rn
[16
]
11
BT
(st
op
-st
art
+
de
vic
e)
W
a
itl
is
t
P
=
N
R
N
ot
si
gn
ific
an
t
B
eh
av
io
ra
l+
dr
ug
th
er
ap
ie
s
v
s.
dr
ug
al
on
e
IE
LT
(m
inu
tes
)
Li
e
ta
l.
[19
]
90
BT
(P
S
+
SS
)+
ch
lo
rp
ro
m
az
in
e
Ch
lo
rp
ro
m
az
in
e
1.
11
(0.
86
to
1.
36
),
P
<
0.
00
01
BT
+
dr
ug
Yu
a
n
e
ta
l.
[21
]
64
BT
(st
op
-st
art
)+
ci
ta
lo
pr
am
Ci
ta
lo
pr
am
0.
46
(0.
04
to
0.
88
),
P
=
0.
03
BT
+
dr
ug
Eja
cu
lat
ory
la
te
nc
y
(C
IP
E-
5)
Li
e
ta
l.
[19
]
90
BT
(P
S
+
SS
)+
ch
lo
rp
ro
m
az
in
e
Ch
lo
rp
ro
m
az
in
e
P
<
0.
05
BT
+
dr
ug
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)+
pa
ro
xe
tin
e
Pa
ro
xe
tin
e
0.
46
(0.
04
to
0.
88
),
P
=
0.
03
BT
+
dr
ug
Se
xu
al
sa
tis
fa
ct
io
n
Li
e
ta
l.
[19
]
90
BT
(P
S
+
SS
)+
ch
lo
rp
ro
m
az
in
e
Ch
lo
rp
ro
m
az
in
e
P
<
0.
05
BT
+
dr
ug
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)+
pa
ro
xe
tin
e
Pa
ro
xe
tin
e
P
<
0.
05
BT
+
dr
ug
Yu
a
n
e
ta
l.
[21
]
64
BT
(st
op
-st
art
)+
ci
ta
lo
pr
am
Ci
ta
lo
pr
am
P
=
N
R
(st
ate
sf
av
or
s
BT
+
dr
ug
)
Un
cle
ar
Eja
cu
lat
ory
co
n
tro
l
Li
e
ta
l.
[19
]
90
BT
(P
S
+
SS
)+
ch
lo
rp
ro
m
az
in
e
Ch
lo
rp
ro
m
az
in
e
P
<
0.
05
BT
+
dr
ug
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)+
pa
ro
xe
tin
e
Pa
ro
xe
tin
e
P
<
0.
01
BT
+
dr
ug
An
xi
et
y
Li
e
ta
l.
[19
]
90
BT
(P
S
+
SS
)+
ch
lo
rp
ro
m
az
in
e
Ch
lo
rp
ro
m
az
in
e
P
<
0.
05
BT
+
dr
ug
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)+
pa
ro
xe
tin
e
Pa
ro
xe
tin
e
P
<
0.
01
BT
+
dr
ug
B
eh
av
io
ra
lt
he
ra
py
v
s.
dr
ug
tr
ea
tm
en
t
IE
LT
(m
inu
tes
)
Ab
de
l-H
am
id
e
ta
l.
[22
]
31
BT
(sq
ue
ez
e)
Pa
ro
xe
tin
e
N
ot
re
po
rte
d
D
ru
g
Se
rtr
al
in
e
N
ot
si
gn
ific
an
t
Cl
om
ip
ra
m
in
e
N
ot
si
gn
ific
an
t
Si
ld
en
afi
l
D
ru
g
Pa
st
or
e
e
ta
l.
[11
]
40
BT
(pe
lvi
cfl
oo
r)
D
ap
ox
et
in
e
−1
.2
2
(−1
.6
5
to
−0
.7
9),
P
<
0.
00
00
1
D
ru
g
Yu
a
n
e
ta
l.
[21
]
64
BT
(st
op
-st
art
)
Ci
ta
lo
pr
am
−3
.5
5
(−3
.8
8
to
−3
.2
2),
P
<
0.
00
00
1
D
ru
g
Eja
cu
lat
ory
la
te
nc
y
(C
IP
E-
5)
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)
Pa
ro
xe
tin
e
−0
.2
0
(−0
.4
0
to
0.
00
),
p=
0.
05
D
ru
g
Se
xu
al
sa
tis
fa
ct
io
n
Ab
de
l-H
am
id
e
ta
l.
[22
]
31
BT
(sq
ue
ez
e)
Pa
ro
xe
tin
e
N
ot
re
po
rte
d
D
ru
g
Se
rtr
al
in
e
N
ot
si
gn
ific
an
t
Cl
om
ip
ra
m
in
e
N
ot
si
gn
ific
an
t
Si
ld
en
afi
l
D
ru
g
O
gu
zh
an
gl
u
e
ta
l.
[23
]
32
BT
(st
op
-st
art
)
Fl
uo
xe
tin
e
P
>
0.
05
N
ot
si
gn
ific
an
t
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)
Pa
ro
xe
tin
e
P
<
0.
01
BT
Yu
a
n
e
ta
l.
[21
]
64
BT
(st
op
-st
art
)
Ci
ta
lo
pr
am
P
=
0.
01
5
D
ru
g
Eja
cu
lat
ory
co
n
tro
l
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)
Pa
ro
xe
tin
e
P
<
0.
01
D
ru
g
An
xi
et
y
Ab
de
l-H
am
id
e
ta
l.
[22
]
31
BT
(sq
ue
ez
e)
Se
e
a
bo
ve
N
ot
re
po
rte
d
N
ot
si
gn
ific
an
t
O
gu
zh
an
gl
u
e
ta
l.
[23
]
32
BT
(st
op
-st
art
)
Fl
uo
xe
tin
e
N
ot
re
po
rte
d
N
ot
si
gn
ific
an
t
Sh
ao
a
n
d
Li
[20
]
80
BT
(va
rio
us
)
Pa
ro
xe
tin
e
P
=
N
R
N
ot
si
gn
ific
an
t
BT
=
be
ha
vio
ra
lt
he
ra
py
;C
I=
co
n
fid
en
ce
in
te
rv
al
;C
IP
E-
5
=
Ch
in
es
e
In
de
x
o
fP
re
m
at
ur
e
Eja
cu
lat
ion
-5;
FS
=
fu
nc
tio
na
l-s
ex
ol
og
ica
l;
G
RI
SS
=
G
ol
om
bo
k
R
us
tI
nv
en
to
ry
o
fS
ex
ua
lS
at
isf
ac
tio
n;
IE
LT
=
in
tra
-v
ag
in
al
e
jac
ula
tor
y
la
te
nc
y
tim
e;
M
D
=
m
e
a
n
di
ffe
re
nc
e;
N
R
=
n
o
tr
e
po
rte
d;
N
S
=
n
o
n
si
gn
ific
an
t;
PE
=
pr
em
at
ur
e
e
jac
ula
tio
n;
PS
=
ps
yc
ho
th
er
ap
y;
R
CT
=
ra
n
do
m
ize
d
co
n
tro
lle
d
tri
al
;R
R
=
ris
k
ra
tio
;S
S
=
st
op
-s
ta
rt.
186 Cooper et al.
Sex Med 2015;3:174–188 © 2015 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
addition to drug treatment. No adverse effects
were reported for BTs, though these were not well
reported across trials. There were generally only
one or two trials of each speciﬁc type of therapy,
which limits the conclusions that can be drawn.
Results of two trials each comparing either two or
three different types of BT indicated that all were
similarly effective [15,17].
Only one RCT, Li et al. [19], included a psycho-
therapeutic approach, comparing chlorpromazine
plus the stop-start technique plus psychotherapy
against chlorpromazine alone. The effectiveness of
psychotherapy in this study was unclear due to the
combined intervention and the use of an active
control. All remaining RCTs focused on physical
techniques as outlined above. Indeed, current PE
guidelines note that the majority of psychotherapy
studies are uncontrolled and nonblinded [1].
Therefore, there remains a need for well-
conducted RCTs of psychotherapeutic approaches
to PE.
Study treatments were relatively well-described
in most studies, though some simply referred to an
established technique (such as stop-start or sensate
focus). Three of the included studies were in
Chinese language. This review used robust meth-
odology including thorough literature searching
and data checking by two reviewers. Non-RCT
studies were not included within this review as
these were considered to be of lower methodologi-
cal quality and would have provided limited infor-
mation on effectiveness.
Duration of the behavioral interventions in the
included studies ranged from 2 to 12 weeks. Three
studies reported that IELT improvements were
maintained 3–6 months after treatment cessation;
however, in general, there is limited data regarding
how long any positive effects would be maintained
after treatment ﬁnishes and whether additional
follow-up treatments might be required. This is a
consideration both for BTs and for drug treat-
ments within PE studies.
The majority of RCTs included an assessment
of either IELT or another measure of ejaculatory
latency, though the method of IELT measurement
(e.g., via stopwatch) was not always reported.
Many RCTs also reported other outcomes such as
ejaculatory control, sexual satisfaction, and anxiety,
though various different measures were used to
assess these, and data were not always clearly
reported. It is important that clinical studies aim to
assess non-IELT aspects of PE, as highlighted in
the recently updated ISSM deﬁnition of PE, which
includes inability to delay ejaculation and negative
personal consequences in addition to reduced
latency time [1].
In comparison with a pharmacological treat-
ment, most BTs require a willingness of the man
and his partner to engage with the therapy and
practice the relevant techniques. The suitability of
a BT is likely to depend on individual patient (and
partner) preference; some people may prefer a
behavioral option, whereas others may prefer
a pharmacological approach. Combinations of
medical and psychological approaches may be
useful where there is a clear psychosocial or rela-
tionship issue [1].
In order to increase consistency in outcome
data and facilitate meta-analyses, future studies
should aim to recruit men meeting the ISSM deﬁ-
nition of PE, measure stopwatch-assessed IELT,
and report other aspects of PE in addition to IELT
using validated instruments.
Further research may focus on psychotherapeu-
tic or counseling approaches for PE, for which few
RCTs were identiﬁed in the current evidence base.
Combination therapy may also be worthy of
further study; this may include combinations of
physical techniques and counseling approaches,
and/or behavioral and drug treatments. Additional
areas for further study may include assessment of
differences between types of BT, optimum dura-
tion of therapy, and how effects might best be
maintained long-term.
Conclusions
There is limited evidence that physical behavioral
techniques for PE improve IELT and other out-
comes over waitlist control. There is also some
evidence that BTs combined with drug treat-
ments improve IELT and other outcomes com-
pared with drug treatments alone. Areas for
further research might include: RCTs of psycho-
therapeutic or counseling approaches to PE;
further studies of combination therapy (physical/
behavioral and/or counseling and/or drug); and
assessment of how effects of therapy might be
maintained long-term.
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